We discover and deliver next generation cell medicines to improve the lives of patients.
Our platform technology immune “cloaks” human pluripotent stem cells and their adult derivatives enabling the development of true ‘off-the-shelf’ cell transplantation therapies.
Combined with an unparalleled expertise in generating stem cell-derived adult T, NK and B cells, Clade promises to become a leading innovator in developing widely accessible cell medicines.
The company is initially focused on harnessing the potential of “cloaked” immune cells for cancer treatment.
Clinical and Scientific Advisors
At Clade Therapeutics, we look for exceptional people who thrive in entrepreneurial environments – those who are motivated by achieving something bigger than themselves, in close collaboration with colleagues.
We are proud to offer a robust Total Reward package that includes a competitive base salary, annual cash bonus program, stock options, work/life flexibility, 401(k) with company contribution, and a comprehensive benefits offering that includes a Health Savings Account with generous company contribution.
Clade Therapeutics Announces the Appointment of Derek Hei, Ph.D., as Chief Technology Officer
Dr. Hei has spent over two decades leading manufacturing teams at biotechnology companies and has deep expertise in the cell therapy space CAMBRIDGE, Mass. – March 10, 2022 – Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced the appointment of Derek Hei, Ph.D., as its
Clade Therapeutics Raises $87 Million Series A Financing to Realize the Potential of Cell Therapy
Clade’s iPSC immune cloaking and differentiation platform technology to address compatibility, durability, reproducibility and scalability of cell therapies CAMBRIDGE, Mass. – November 3, 2021 – Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, today announced it has secured an $87 million Series A financing led by Syncona